Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Mar 31, 2026
Soligenix, Inc. (SNGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.8 million in cash and investments and $302,589 in total debt.
Revenue
$0
Net income
$-1.99M
+26.4% vs year-ago quarter
Operating cash flow
$-1.71M
+37.8% vs year-ago quarter
Free cash flow
$-2.75M
+6.5% vs prior quarter
EPS
$-0.12
+85.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
21.77M
+407.9% vs year-ago quarter
Net cash
$9.51M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 812796
- Former names
- SOLIGENIX, INC. (until Nov 6, 2026); DOR BIOPHARMA INC (until Sep 29, 2009); ENDOREX CORP (until Oct 24, 2001); IMMUNOTHERAPEUTICS INC (until Apr 30, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.1M | -$2.9M | -$3.5M | -$2.6M | -$2.8M |
| Net income | -$2.0M | -$2.8M | -$2.9M | -$2.5M | -$2.7M |
| Diluted EPS | -$0.12 | -$0.28 | -$0.29 | -$0.58 | -$0.82 |
| Operating cash flow | -$1.7M | -$2.4M | -$2.7M | -$2.9M | -$2.7M |
| Free cash flow | — | — | -$2.7M | -$2.9M | -$2.7M |
| Total assets | $10.5M | $6.9M | $9.2M | $11.3M | $5.8M |
| Total liabilities | $3.9M | $3.8M | $3.9M | $3.7M | $3.9M |
| Stockholders' equity | $6.6M | $3.1M | $5.3M | $7.6M | $1.8M |
| Cash and investments | $9.8M | $6.0M | $7.9M | $10.5M | $5.1M |
| Total debt | $302,589 | $330,660 | $358,144 | $385,054 | $411,403 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results, Other events
|
Sep 21, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Listing notice, Officer or director change, Other events
|
Jun 12, 2026 | Jun 10, 2026 |
All 1006 Soligenix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.